S1PR3

Summary

S1PR3 (sphingosine-1-phosphate receptor 3, HGNC:3167) is a protein-coding gene on chromosome 9q22.1, encoding Sphingosine 1-phosphate receptor 3 (Q99500). Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P).

This gene encodes a member of the EDG family of receptors, which are G protein-coupled receptors. This protein has been identified as a functional receptor for sphingosine 1-phosphate and likely contributes to the regulation of angiogenesis and vascular endothelial cell function.

Source: NCBI Gene 1903 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 62 total — 1 pathogenic, 1 likely-pathogenic
• GTEx eGene: eQTL in 18 tissues, sQTL in 0 (q < 0.05)
• Drug target: yes — 3 via a complex or family; 5 molecules with ChEMBL bioactivity
• Approved drugs acting on a complex or family including it: 2 — Fingolimod Hydrochloride, Fingolimod Lauryl Sulfate (Sphingosine 1-phosphate receptor)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.27 (unconstrained)
• MANE Select transcript: NM_005226
• Notable: 62 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3167
Approved symbol	S1PR3
Name	sphingosine-1-phosphate receptor 3
Location	9q22.1
Locus type	gene with protein product
Status	Approved
Aliases	EDG-3, FLJ37523, bA791O21.3
Ensembl gene	ENSG00000213694
Ensembl biotype	protein_coding
OMIM	601965
Entrez	1903

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 3 protein_coding_CDS_not_defined

MANE Select: ENST00000358157

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 2, TSL 3: 1

ENST00000358157, ENST00000334490, ENST00000375846, ENST00000375850, ENST00000648341, ENST00000887789, ENST00000887792, ENST00000887793, ENST00000968554, ENST00000968555, ENST00000968556, ENST00000968557, ENST00001137251

RefSeq mRNA: 2 — MANE Select: NM_005226 NM_001395848, NM_005226

CCDS: CCDS6680

Canonical transcript exons

ENST00000358157 — 2 exons

Exon	Start	End
ENSE00001331415	89001054	89005155
ENSE00001407961	88991468	88991695

Expression profiles

Bgee: expression breadth ubiquitous, 236 present calls, max score 97.78.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.7330 / max 183.3777, expressed in 1346 samples.

Highest expression (Bgee): ventricle myocardium, decidua, lower esophagus muscularis layer, lower esophagus, cardiac muscle of right atrium.

Genetic regulation across tissues (GTEx eQTL / sQTL)

S1PR3 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 18 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

18 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Stomach	eqtl	1.9e-18	-0.29	9:88942544:G:A
Skin Sun Exposed Lower leg	eqtl	1.3e-14	-0.28	9:88810039:G:A
Skin Not Sun Exposed Suprapubic	eqtl	5.7e-08	-0.22	9:88801833:T:C
Spleen	eqtl	1.1e-05	-0.36	9:88805305:C:T
Pancreas	eqtl	1.8e-05	+0.26	9:88963885:T:G
Muscle Skeletal	eqtl	1.9e-05	+0.31	9:88888321:C:G
Whole Blood	eqtl	1.3e-04	-0.74	9:88917421:G:T
Lung	eqtl	6.7e-04	+0.55	9:88956138:A:T
Breast Mammary Tissue	eqtl	1.4e-03	-0.20	9:88847680:A:G
Esophagus Gastroesophageal Junction	eqtl	1.4e-03	+0.13	9:88990394:A:AGAATC
Esophagus Muscularis	eqtl	1.4e-03	+0.10	9:88976258:A:G
Cells Cultured fibroblasts	eqtl	3.0e-03	+0.21	9:88812862:A:G
Nerve Tibial	eqtl	9.3e-03	+0.11	9:88975188:T:C
Brain Amygdala	eqtl	2.0e-02	-0.90	9:88115969:A:C
Testis	eqtl	2.6e-02	-0.12	9:88865272:C:G
Adrenal Gland	eqtl	2.9e-02	-0.20	9:88904493:T:C
Adipose Visceral Omentum	eqtl	3.7e-02	+0.41	9:89373432:G:A
Colon Sigmoid	eqtl	5.0e-02	+0.13	9:88990394:A:AGAATC

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
97276	11.7330	1346

Top tissues by expression

showing 100 of 249 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left ventricle myocardium	UBERON:0006566	97.78	gold quality
decidua	UBERON:0002450	95.88	gold quality
lower esophagus muscularis layer	UBERON:0035833	95.87	gold quality
lower esophagus	UBERON:0013473	95.76	gold quality
cardiac muscle of right atrium	UBERON:0003379	95.24	gold quality
ventricular zone	UBERON:0003053	94.88	gold quality
heart right ventricle	UBERON:0002080	94.77	gold quality
right coronary artery	UBERON:0001625	94.66	gold quality
left coronary artery	UBERON:0001626	94.46	gold quality
coronary artery	UBERON:0001621	94.26	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	94.16	gold quality
cauda epididymis	UBERON:0004360	93.29	gold quality
descending thoracic aorta	UBERON:0002345	93.14	gold quality
superficial temporal artery	UBERON:0001614	93.10	gold quality
thoracic aorta	UBERON:0001515	92.96	gold quality
stromal cell of endometrium	CL:0002255	92.95	gold quality
myocardium	UBERON:0002349	92.82	gold quality
ascending aorta	UBERON:0001496	92.72	gold quality
aorta	UBERON:0000947	92.57	gold quality
popliteal artery	UBERON:0002250	92.33	gold quality
tibial artery	UBERON:0007610	92.29	gold quality
mucosa of stomach	UBERON:0001199	91.79	gold quality
metanephros	UBERON:0000081	91.66	gold quality
synovial joint	UBERON:0002217	91.63	gold quality
metanephros cortex	UBERON:0010533	91.51	gold quality
placenta	UBERON:0001987	91.29	gold quality
left uterine tube	UBERON:0001303	90.85	gold quality
tibia	UBERON:0000979	90.70	gold quality
smooth muscle tissue	UBERON:0001135	89.40	gold quality
pericardium	UBERON:0002407	89.35	gold quality
endocervix	UBERON:0000458	89.00	gold quality
left adrenal gland	UBERON:0001234	88.37	gold quality
monocyte	CL:0000576	88.21	gold quality
adrenal gland	UBERON:0002369	87.99	gold quality
left adrenal gland cortex	UBERON:0035825	87.96	gold quality
vena cava	UBERON:0004087	87.89	gold quality
adrenal cortex	UBERON:0001235	87.84	gold quality
leukocyte	CL:0000738	87.70	gold quality
mammalian vulva	UBERON:0000997	87.66	gold quality
kidney epithelium	UBERON:0004819	87.45	silver quality
ectocervix	UBERON:0012249	87.24	gold quality
uterine cervix	UBERON:0000002	86.99	gold quality
saphenous vein	UBERON:0007318	86.75	gold quality
layer of synovial tissue	UBERON:0007616	86.57	gold quality
epithelial cell of pancreas	CL:0000083	86.53	silver quality
heart	UBERON:0000948	86.50	gold quality
urethra	UBERON:0000057	86.44	gold quality
endometrium	UBERON:0001295	86.40	gold quality
right adrenal gland cortex	UBERON:0035827	86.28	gold quality
caput epididymis	UBERON:0004358	86.26	gold quality
cardiac ventricle	UBERON:0002082	85.86	gold quality
right adrenal gland	UBERON:0001233	85.84	gold quality
endothelial cell	CL:0000115	85.70	silver quality
heart left ventricle	UBERON:0002084	85.68	gold quality
urinary bladder	UBERON:0001255	85.62	gold quality
seminal vesicle	UBERON:0000998	85.45	gold quality
cardiac atrium	UBERON:0002081	85.44	gold quality
uterus	UBERON:0000995	85.18	gold quality
gall bladder	UBERON:0002110	85.14	gold quality
prostate gland	UBERON:0002367	84.98	gold quality
right atrium auricular region	UBERON:0006631	84.93	gold quality
cardia of stomach	UBERON:0001162	84.89	gold quality
esophagus	UBERON:0001043	84.00	gold quality
ganglionic eminence	UBERON:0004023	84.00	gold quality
kidney	UBERON:0002113	83.52	gold quality
body of uterus	UBERON:0009853	83.48	gold quality
myometrium	UBERON:0001296	83.34	gold quality
adult mammalian kidney	UBERON:0000082	83.09	gold quality
tibialis anterior	UBERON:0001385	82.85	silver quality
vagina	UBERON:0000996	82.84	gold quality
pituitary gland	UBERON:0000007	82.52	gold quality
renal medulla	UBERON:0000362	82.36	gold quality
apex of heart	UBERON:0002098	82.36	gold quality
adenohypophysis	UBERON:0002196	81.96	gold quality
corpus epididymis	UBERON:0004359	81.78	gold quality
omental fat pad	UBERON:0010414	81.67	gold quality
peritoneum	UBERON:0002358	81.66	gold quality
lymph node	UBERON:0000029	81.50	gold quality
adrenal tissue	UBERON:0018303	81.49	gold quality
epithelium of mammary gland	UBERON:0003244	81.23	gold quality
muscle layer of sigmoid colon	UBERON:0035805	81.23	gold quality
mammary duct	UBERON:0001765	81.10	gold quality
adipose tissue of abdominal region	UBERON:0007808	81.08	gold quality
vermiform appendix	UBERON:0001154	80.99	gold quality
female reproductive system	UBERON:0000474	80.87	gold quality
islet of Langerhans	UBERON:0000006	80.62	gold quality
penis	UBERON:0000989	79.73	gold quality
caecum	UBERON:0001153	79.73	gold quality
spleen	UBERON:0002106	79.12	gold quality
fundus of stomach	UBERON:0001160	79.02	gold quality
trigeminal ganglion	UBERON:0001675	78.73	gold quality
upper lobe of lung	UBERON:0008948	78.70	gold quality
upper lobe of left lung	UBERON:0008952	78.67	gold quality
ileal mucosa	UBERON:0000331	78.66	gold quality
tibial nerve	UBERON:0001323	78.64	gold quality
lung	UBERON:0002048	78.63	gold quality
thoracic mammary gland	UBERON:0005200	78.62	gold quality
lower lobe of lung	UBERON:0008949	78.61	silver quality
fallopian tube	UBERON:0003889	78.45	gold quality
mammary gland	UBERON:0001911	78.40	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	46.93
E-ANND-3	yes	10.90

HPA expression

RNA tissue specificity: Tissue enhanced

showing 60 of 76 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM
Smooth muscle	tissue	33.6
Adrenal gland	tissue	23.6
Cervix	tissue	19.4
Vagina	tissue	19.2
Choroid plexus	tissue	18.8
Adipose tissue	tissue	17.1
Urinary bladder	tissue	16.7
Esophagus	tissue	16.3
Pituitary gland	tissue	16.0
Endometrium 1	tissue	14.2
Placenta	tissue	14.2
Prostate	tissue	13.5
Gallbladder	tissue	13.3
Spleen	tissue	12.4
Kidney	tissue	11.4
Seminal vesicle	tissue	11.2
Pancreas	tissue	11.0
Lymph node	tissue	10.6
Breast	tissue	10.6
Hippocampus	tissue	10.1
Appendix	tissue	9.8
Fallopian tube	tissue	9.4
Heart muscle	tissue	9.2
Locus coeruleus	tissue	9.1
Tonsil	tissue	8.8
Tongue	tissue	7.7
Epididymis	tissue	5.9
Nucleus accumbens	tissue	5.6
Lung	tissue	5.5
Liver	tissue	5.3
Spinal cord	tissue	4.5
Stomach 1	tissue	4.4
Thymus	tissue	4.4
Duodenum	tissue	4.2
Retina	tissue	3.9
Colon	tissue	3.9
Frontal cortex	tissue	3.8
Salivary gland	tissue	3.7
Postcentral gyrus	tissue	3.7
Thyroid gland	tissue	3.4
Small intestine	tissue	3.3
Rectum	tissue	3.2
Caudate putamen	tissue	3.1
Bone marrow	tissue	3.0
Pons	tissue	2.9
Ovary	tissue	2.2
Testis	tissue	2.1
Olfactory bulb	tissue	2.0
Cerebral cortex	tissue	1.7
Substantia nigra	tissue	1.7
Occipital cortex	tissue	1.7
Parathyroid gland	tissue	1.6
Hypothalamus	tissue	1.6
Hippocampal formation	tissue	1.6
Septum	tissue	1.6
Ventral forebrain	tissue	1.5
Prefrontal cortex	tissue	1.4
Skeletal muscle	tissue	1.4
Motor cortex	tissue	1.4
Entorhinal cortex	tissue	1.4

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Blood vessel (59.3), Area postrema (30.8), Anterior thalamic nucleus, ventral (23.8), Dorsal funiculus (white matter) (23.5), Supraoptic nucleus (20.9).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting S1PR3 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 106 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-3689D	100.00	66.14	1181
HSA-MIR-6851-5P	100.00	65.63	1294
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-5688	99.96	73.23	4504
HSA-MIR-495-3P	99.96	72.81	4197
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-627-3P	99.90	71.42	3316
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-6783-3P	99.89	67.92	2059
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-605-3P	99.88	69.22	1833
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-3140-3P	99.88	68.47	2069

Functional genomics

gnomAD constraint: pLI 0.000169, LOEUF 1.27, missense Z 1.29 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000358157 — one region, missense o/e 0.90.

Literature-anchored findings (GeneRIF, showing 40)

• activates Rho family G proteins and cell motility (PMID:11915348)
• a 9-amino acid peptide (KRX-725), derived from the second intracellular loop of S1P3 (EDG3) mimics sphingosine 1-phosphate (S1P) by triggering a Gi-dependent mitogen-activated protein kinase kinase and extracellular signal-regulated kinase signal. (PMID:12763936)
• S1P(3) function is not subject to conventional regulation by GRK phosphorylation (PMID:15894172)
• Expression of the sphingosine 1 phosphate receptor in primary endothelial cells is both sufficient and necessary for the expression of Akt3. (PMID:16527273)
• Sphingosine 1-phosphate-induced inflammatory response genes expression is mediated through S1P(1) and S1P(3) (PMID:17331465)
• Reults describe the role of mu opioid receptors and S1P3 transactivation in the attenuation of vascular permeability by methylnaltrexone. (PMID:17395891)
• Cytosolic phospholipase A2alpha activation induced by S1P is mediated by the S1P3 receptor in lung epithelial cells.( (PMID:18502815)
• Results suggest that S1PR3 is involved in COX2 dependent effects of high-density lipoprotein on vascular smooth muscle. (PMID:18612546)
• Plays essential roles in the pathogenesis of rheumatoid arthritis by modulating fibroblast-like synoviocyte migration, cytokine/chemokine production, and cell survival. (PMID:18658144)
• Report different response patterns of several ligands at the sphingosine-1-phosphate receptor subtype 3 (S1P(3)). (PMID:19309361)
• IGFBP-3 in MCF-10A cells requires SphK1 activity and S1P1/S1P3, suggesting that S1P, the product of SphK activity and ligand for S1P1 and S1P3 (PMID:19633297)
• amplification of SHC3 and EDG3 genes suggests that the two proteins co-operate and are important for ependymomas in vivo. (PMID:19748727)
• this study demonstrated that reactive astrocytes in MS lesions and cultured under proinflammatory conditions strongly enhance expression of S1P receptors 1 and 3. (PMID:20648639)
• These results support a model in which the interaction between sphingosine kinase 1, sphingosine 1-phosphate receptors 1 and/or 3, and ERK-1/2 might drive breast cancer progression (PMID:20889557)
• These results suggest a potential role for HDL and S1P receptors in the pathogenesis of prostate cancer. (PMID:20979115)
• The follicular fluid-HDL-associated S1P promotes granulosa lutein cell migration via S1PR3 and RAC1 activation. This may represent a novel mechanism contributing to the development of the corpus luteum. (PMID:20980685)
• SphK/S1P/S1PRs signaling axis plays an important role in liver fibrosis and is involved in the directed migration of hepatic myofibroblasts into the damaged areas. (PMID:21145832)
• S1P regulates MMP-9 induction and invasiveness through coupling of S1P3 and G(alphaq) in MCF10A cells, thus providing a molecular basis for the crucial role of S1P in promoting breast cell invasion. (PMID:21652634)
• These data have identified an additional function regulated by S1P/S1PR1,3 axis involving migration and fibrogenic activation of hepatic stellate cells. (PMID:21660960)
• S1PR3 was higher in iliac-femoral arteries compared with carotid arteries. (PMID:22308044)
• Suggest that the enhanced S1P3-EGFR signaling axis may contribute to the tumorigenesis or progression of lung adenocarcinomas. (PMID:22344462)
• abdominal aortic aneurysms have down-regulation of the S1P2 protein with simultaneous up-regulation of the S1P3 protein, but not S1P1 (PMID:22547907)
• However, growing evidence strongly suggests that the assessment of Sphingosine-1-phosphate receptor 1/3 (S1P1/3) own advantages over present measurements in predicting the risk of developing diabetic cardiovascular diseases. (PMID:22595806)
• S1PR3 is nitrated on specific tyrosine residues and released as endothelial cell microparticles during acute lung injury. (PMID:22771388)
• S1P receptors S1P1,2,3 are expressed in human anaplastic thyroid cancer C643 and THJ-16T cells at both mRNA and protein levels (PMID:22889737)
• Inhibition of S1P3 receptors prevented E2-induced activation of Cdc42, supporting the important role of the S1P receptor in E2 signaling. (PMID:23142484)
• S1P3 receptors are detected in virtually all neurons in dorsal root ganglion and mediate pain behavior. (PMID:23392686)
• key role of Sphk1, S1PR1 and S1PR3 in angiogenesis underlying the liver fibrosis process (PMID:23466305)
• S1PR agonists are pro-fibrotic via S1P2R and S1P3R stimulation using Smad-independent pathways. (PMID:23589284)
• associations were found for 2 promoter SNPs across 2 European descent samples supporting association of alleles -1899G and -1785C with decreased risk for sepsis-associated acute respiratory distress syndrome (ARDS); alleles reduced transcription factor binding to S1PR3 promoter and S1PR3 promoter activity; associated with lower plasma S1PR3 protein in ARDS patients (PMID:23911438)
• Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis. (PMID:23918395)
• we provide evidences that S1PR1/3, but not S1PR2, negatively regulate the expression of collagen in hMSCs using cellular and molecular approaches in vitro (PMID:24038457)
• a novel signaling axis, i.e., ROCK-JNK-ETS-1-CD44 pathway, which plays an essential role in the S1P3-regulated chemotactic response. (PMID:24064218)
• Data indicate that sphingosine 1-phosphate (S1P) and hepatocyte growth factor (HGF) induced transloaction of integrin beta4, S1P receptors S1PR2 and S1PR3 to endothelial cell membrane caveolin-enriched microdomains (CEMs). (PMID:24851274)
• Data show that sphingosine kinase SphK1 and sphingosine-1-phosphate (S1P) receptors S1P1, S1P2, S1P3, and S1P5 were expressed from primary, up to recurrent and secondary glioblastomas, with sphingosine kinase SphK2 levels were highest in primary tumors. (PMID:24903384)
• Stimulation with sphingosine-1-phosphate enhances cancer stem cells via S1PR3 and subsequent Notch1 activation. (PMID:25254944)
• S1pr3 promotes leukocyte rolling by mobilization of endothelial P-selectin. (PMID:25832730)
• TRPC1 functions as a major regulator of S1P3 and VEGFR2 expression. (PMID:25971967)
• The S1P1,3 activation results in Akt phosphorylation and subsequent activation of eNOS via phosphorylation at serine(1177) and dephosphorylation at threonine(495). (PMID:27282481)
• in breast cancer cells overexpression of S1P3 and its activation by S1P has pro-inflammatory and pro-metastatic potential by inducing COX-2 expression and PGE2 signaling via EP2 and EP4. (PMID:27616330)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	S1pr3	ENSMUSG00000067586
rattus_norvegicus	S1pr3	ENSRNOG00000014524

Paralogs (18): LPAR2 (ENSG00000064547), CNR1 (ENSG00000118432), MC3R (ENSG00000124089), S1PR4 (ENSG00000125910), GPR12 (ENSG00000132975), GPR6 (ENSG00000146360), GPR119 (ENSG00000147262), MC4R (ENSG00000166603), S1PR1 (ENSG00000170989), LPAR3 (ENSG00000171517), MC5R (ENSG00000176136), S1PR5 (ENSG00000180739), GPR3 (ENSG00000181773), MC2R (ENSG00000185231), CNR2 (ENSG00000188822), LPAR1 (ENSG00000198121), MC1R (ENSG00000258839), S1PR2 (ENSG00000267534)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:1339365) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 12 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal retina morphology	1
male infertility	1
female infertility	1
decreased litter size	1
abnormal B cell physiology	1
abnormal cell physiology	1
enlarged mesenteric lymph nodes	1
abnormal cytokine level	1
decreased susceptibility to endotoxin shock	1
decreased susceptibility to induced morbidity/mortality	1
abnormal retina blood vessel morphology	1
abnormal skin coloration	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Macaca fascicularis	Q95KH4	98.6%	Diamond
Xenopus laevis	Q9PU16	98.4%	Diamond
Ovis aries	P46628	97.8%	Diamond
Bos taurus	Q28031	97.8%	Diamond
Sus scrofa	Q684M3	86.7%	Diamond
Taricha granulosa	Q9PUI7	86.7%	Diamond
Takifugu rubripes	Q98894	75.1%	Diamond
Danio rerio	Q9DDK4	71.7%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
MIR4289	ncRNA	100423015
SHC3	protein-coding	53358
MIR3153	ncRNA	100422936
SEMA4D	protein-coding	10507
CKS2	protein-coding	1164
SECISBP2	protein-coding	79048
LINC02843	ncRNA	286238

Protein

Protein identifiers

Sphingosine 1-phosphate receptor 3 — Q99500 (reviewed: Q99500)

Alternative names: Endothelial differentiation G protein-coupled receptor 3, Sphingosine 1-phosphate receptor Edg-3

All UniProt accessions (1): Q99500

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P). S1P is a bioactive lysophospholipid that elicits diverse physiological effect on most types of cells and tissues. When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis.

Subcellular location. Cell membrane.

Tissue specificity. Expressed in all tissues, but most abundantly in heart, placenta, kidney, and liver.

Similarity. Belongs to the G protein-coupled receptor 1 family.

RefSeq proteins (2): NP_001382777, NP_005217* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR004061	S1P_rcpt	Family
IPR004062	EDG3_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (43 total): helix 13, topological domain 8, transmembrane region 7, turn 4, strand 4, chain 1, region of interest 1, compositionally biased region 1, modified residue 1, glycosylation site 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

9 structures by resolution:

PDB	Title	Method	Resolution (Å)
9W0H	S1P3 in complex with cpd-32 and spm242	X-RAY DIFFRACTION	3
9W0O	cryoEM structure of S1P3 in complex with heterotrimeric G protein	ELECTRON MICROSCOPY	3
7EW2	Cryo-EM structure of pFTY720-bound Sphingosine 1-phosphate receptor 3 in complex with Gi …	ELECTRON MICROSCOPY	3.1
7EW3	Cryo-EM structure of S1P-bound Sphingosine 1-phosphate receptor 3 in complex with Gi …	ELECTRON MICROSCOPY	3.1
7C4S	Sphingosine-1-phosphate receptor 3 with a natural ligand.	X-RAY DIFFRACTION	3.2
7EW4	Cryo-EM structure of CYM-5541-bound Sphingosine 1-phosphate receptor 3 in complex with Gi …	ELECTRON MICROSCOPY	3.2
9WP9	Cryo-EM structure of the d18:1 S1P-bound S1PR3 and Gq complex	ELECTRON MICROSCOPY	3.25
9W0L	S1P3 in complex with CYM52581 and spm242	X-RAY DIFFRACTION	3.6
9L74	Cryo-EM structure of the d16:1 S1P-bound S1PR3 and Gq complex	ELECTRON MICROSCOPY	3.73

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q99500-F1	79.81	0.50

Antibody-complex structures (SAbDab)

5 antibodies co-crystallized with this protein: 7C4S, 7EW2, 7EW3, 7EW4, 9WP9

Human Protein Atlas

Protein class: G-protein coupled receptors, GPCRs excl olfactory receptors, Lysolipids receptors, Predicted membrane proteins, GPCRHMM predicted membrane proteins, FDA approved drug targets, Small molecule drugs

Protein evidence: Evidence at protein level

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Phosphoserine	326

Glycosylation sites (1)

Type	Positions
N-linked (glcnac…) asparagine	15

Function

Pathways and Gene Ontology

Reactome pathways

3 curated (TAS) of 10; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

10 pathways:

ID	Pathway	Evidence
R-HSA-9009391	Extra-nuclear estrogen signaling	curated
R-HSA-418594	G alpha (i) signalling events	curated
R-HSA-419408	Lysosphingolipid and LPA receptors	curated
R-HSA-373076	Class A/1 (Rhodopsin-like receptors)	—
R-HSA-8939211	ESR-mediated signaling	—
R-HSA-388396	GPCR downstream signalling	—
R-HSA-500792	GPCR ligand binding	—
R-HSA-162582	Signal Transduction	—
R-HSA-372790	Signaling by GPCR	—
R-HSA-9006931	Signaling by Nuclear Receptors	—

MSigDB gene sets: 246 (showing top): GSE37336_LY6C_POS_VS_NEG_NAIVE_CD4_TCELL_DN, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_ENDOTHELIAL_CELL_DEVELOPMENT, WILLIAMS_ESR1_TARGETS_DN, GOBP_EPITHELIUM_DEVELOPMENT, GOBP_NEGATIVE_REGULATION_OF_CELL_DEVELOPMENT, GOBP_INFLAMMATORY_RESPONSE, GOBP_EPITHELIAL_CELL_DEVELOPMENT, GOBP_SPHINGOLIPID_MEDIATED_SIGNALING_PATHWAY, GAUSSMANN_MLL_AF4_FUSION_TARGETS_A_UP, GOBP_REGULATION_OF_ENDOTHELIAL_CELL_DIFFERENTIATION, GOBP_INTERLEUKIN_1_PRODUCTION, CLASPER_LYMPHATIC_VESSELS_DURING_METASTASIS_DN, GOBP_REGULATION_OF_ENDOTHELIAL_CELL_DEVELOPMENT

GO Biological Process (9): inflammatory response (GO:0006954), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-activating G protein-coupled receptor signaling pathway (GO:0007189), positive regulation of cytosolic calcium ion concentration (GO:0007204), positive regulation of cell population proliferation (GO:0008284), anatomical structure morphogenesis (GO:0009653), negative regulation of establishment of endothelial barrier (GO:1903141), sphingosine-1-phosphate receptor signaling pathway (GO:0003376), signal transduction (GO:0007165)

GO Molecular Function (5): G protein-coupled receptor activity (GO:0004930), integrin binding (GO:0005178), lipid binding (GO:0008289), sphingosine-1-phosphate receptor activity (GO:0038036), protein binding (GO:0005515)

GO Cellular Component (4): cytoplasm (GO:0005737), plasma membrane (GO:0005886), presynapse (GO:0098793), membrane (GO:0016020)

Reactome top-level categories

7 top-level categories:

Category	Pathways
Signal Transduction	2
Signaling by GPCR	2
GPCR downstream signalling	1
Class A/1 (Rhodopsin-like receptors)	1
ESR-mediated signaling	1
GPCR ligand binding	1
Signaling by Nuclear Receptors	1

GO top-level categories

33 GO namespaces:

Category	Terms
cellular anatomical structure	3
G protein-coupled receptor signaling pathway	2
binding	2
defense response	1
G protein-coupled receptor activity	1
signal transduction	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase activator activity	1
regulation of biological quality	1
cell population proliferation	1
regulation of cell population proliferation	1
positive regulation of cellular process	1
developmental process	1
anatomical structure development	1
establishment of endothelial barrier	1
negative regulation of endothelial cell development	1
regulation of establishment of endothelial barrier	1
sphingolipid mediated signaling pathway	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
transmembrane signaling receptor activity	1
signaling receptor binding	1
protein-containing complex binding	1
cell adhesion molecule binding	1
sphingosine-1-phosphate receptor signaling pathway	1
bioactive lipid receptor activity	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
synapse	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 18 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
negative regulation of establishment of endothelial barrier	BP	mutant phenotype
plasma membrane	CC	direct assay
integrin binding	MF	physical interaction

Protein interactions and networks

STRING

showing 15 of 806 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
S1PR3	SPHK1	Q9NYA1	923
S1PR3	SPHK2	Q9NRA0	874
S1PR3	F2R	P25116	780
S1PR3	F2RL1	P55085	739
S1PR3	GNA15	P30679	694
S1PR3	SPNS2	Q8IVW8	668
S1PR3	PITRM1	Q5JRX3	667
S1PR3	MFSD2B	A6NFX1	651
S1PR3	PROCR	Q9UNN8	638
S1PR3	APOM	O95445	580
S1PR3	SGPL1	O95470	579
S1PR3	ARRB1	P49407	565
S1PR3	CCL2	P13500	564
S1PR3	AKT1	P31749	554
S1PR3	ALDH18A1	P54886	551

IntAct

Human interaction partners of S1PR3 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

4 partners by confidence:

Partner	Interaction type	MIscore	Records
COMT	physical association	0.560	3
GYPB	physical association	0.560	3
ITGB4	physical association	0.470	3
STXBP3	association	0.350	1

BioGRID (15 interactions; top human partners by supporting records): ARID1A (Negative Genetic), COMT (Two-hybrid), GYPB (Two-hybrid), HTR1A (Affinity Capture-Western)

SIGNOR signaling

13 signaling interactions:

A	Effect	B	Mechanism
“sphingosine 1-phosphate”	up-regulates	S1PR3	“chemical activation”
S1PR3	“up-regulates activity”	GNAS	binding
S1PR3	“up-regulates activity”	GNAL	binding
S1PR3	“up-regulates activity”	GNAI1	binding
S1PR3	“up-regulates activity”	GNAI3	binding
S1PR3	“up-regulates activity”	GNAO1	binding
S1PR3	“up-regulates activity”	GNAZ	binding
S1PR3	“up-regulates activity”	GNAQ	binding
S1PR3	“up-regulates activity”	GNA14	binding
“sphingosine 1-phosphate(1-)”	“up-regulates activity”	S1PR3	“chemical activation”
S1PR3	up-regulates	GNA13	binding
S1PR3	up-regulates	GNAI1	binding
“sphingosine 1-phosphate”	“up-regulates activity”	S1PR3	“chemical activation”

Protein complexes (CORUM) (9)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

9 complexes by size:

Complex	Subunits	Members
★ KDR-MAPK1-MAPK3-PRKCA-S1PR3 complex	5	S1PR3, KDR, MAPK1, MAPK3, PRKCA
★ LPAR1-S1PR3 complex	2	LPAR1, S1PR3
★ LPAR2-S1PR3 complex	2	LPAR2, S1PR3
★ LPAR3-S1PR3 complex	2	LPAR3, S1PR3
★ GPR4-S1PR3 complex	2	S1PR3, GPR4
★ GPR68-S1PR3 complex	2	GPR68, S1PR3
★ ITGB4-S1PR3 complex	2	ITGB4, S1PR3
★ HTR1A-S1PR3 complex	2	S1PR3, HTR1A
★ Sphingosine 1-phosphate receptor 3	1	S1PR3

Disease & clinical

Genetic variants

Variant evidence for S1PR3: 62 ClinVar records (2 pathogenic / likely pathogenic); 12 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

62 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	1
Uncertain significance	56
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (2)

Showing all 2 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
57292	GRCh38/hg38 9q21.33-22.2(chr9:87418580-90406012)x1	Pathogenic	criteria provided, single submitter	1
1330172	GRCh37/hg19 9q21.33-22.2(chr9:90342469-93657932)x1	Likely pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore S1PR3’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 19 predictions of 138):

Position(s)	Effect	Δscore	Sites
9:88991696–88991697	donor_loss	0.9900	4
9:88991993	donor_gain	0.9900
9:88991696	donor_loss	0.9800
9:89001048	acceptor_gain	0.8800
9:89001045	acceptor_loss	0.8700
9:89001051–89001053	acceptor_loss	0.8700	7
9:89001043	acceptor_loss	0.8600
9:89001051	acceptor_loss	0.7600
9:88991932	donor_gain	0.7500
9:88991697	donor_loss	0.7400

AlphaMissense

907 missense substitutions predicted likely pathogenic (of 2,495 scored), across 229 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M305	9	0.858	0.979
M74	9	0.856	0.963
D85	8	0.997	0.999
N57	8	0.995	0.998
N294	8	0.995	0.999
D266	8	0.979	0.990
F252	8	0.973	0.997
N290	8	0.940	0.997
F119	8	0.908	0.981
M140	8	0.905	0.985
F260	8	0.898	0.961
F77	8	0.884	0.970
C185	7	0.991	0.996
C178	7	0.986	0.996
W256	7	0.984	0.998
W176	7	0.969	0.995
E135	7	0.965	0.994
W162	7	0.965	0.998
F70	7	0.946	0.983
W111	7	0.946	0.990

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

2 prognostic cancer types:

Cancer	Prognostic	p-value
Lung Adenocarcinoma (validation)	unfavorable	6.85e-05
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000605

Disease associations

OMIM: gene MIM:601965 | disease phenotypes:

GWAS associations

12 associations:

Study	Trait	p-value
GCST90016667_5	Spleen volume	3e-23
GCST006101_5	Cardiometabolic and hematological traits	2e-21
GCST007954_46	Glycated hemoglobin levels	3e-14
GCST90002394_533	Monocyte percentage of white cells	7e-13
GCST004609_119	Monocyte percentage of white cells	9e-10
GCST005991_95	Platelet count	4e-9
GCST006192_15	Systolic blood pressure x smoking status (ever vs never) interaction (2df test)	4e-9
GCST006995_2	Logical memory (delayed recall) in Alzheimer’s disease dementia	7e-8
GCST001408_7	Response to statins (LDL cholesterol change)	7e-7
GCST003472_21	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	1e-6
GCST003472_19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	3e-6
GCST003472_7	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder	3e-6

EFO canonical traits (from GWAS)

8 canonical traits:

EFO ID	Trait name
EFO:0007804	LDL cholesterol change measurement
EFO:0007679	oppositional defiant disorder measurement
EFO:0007989	monocyte percentage of leukocytes
EFO:0004309	platelet count
EFO:0006335	systolic blood pressure
EFO:0006527	smoking status measurement
EFO:0004874	memory performance
EFO:0004541	HbA1c measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (3): CHEMBL2363041 (PROTEIN FAMILY), CHEMBL3430884 (PROTEIN COMPLEX), CHEMBL3892 (SINGLE PROTEIN)

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes S1PR3 — the drug acts on the assembly or class, not necessarily on this subunit alone.

3 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
FINGOLIMOD HYDROCHLORIDE	Sphingosine 1-phosphate receptor	5	4
FINGOLIMOD LAURYL SULFATE	Sphingosine 1-phosphate receptor	5	4
AMISELIMOD HYDROCHLORIDE	Sphingosine 1-phosphate receptor	5	2

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 20,481 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

5 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL314854	FINGOLIMOD	4	16,404
CHEMBL3707247	OZANIMOD	4	1,710
CHEMBL1096146	PONESIMOD	4	753
CHEMBL2336071	SIPONIMOD	4	1,603
CHEMBL3806158	BMS-986104	1	11

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Lysophospholipid (S1P) receptors

Most potent curated ligand interactions (19 total), top 19:

Ligand	Action	Affinity	Parameter
sphingosine 1-phosphate	Agonist	9.64	pKd
AFD(R)	Agonist	9.4	pEC50
SPM-354	Antagonist	9.3	pA2
(S)-FTY720-phosphate	Agonist	8.51	pEC50
fingolimod-phosphate	Agonist	8.3	pIC50
VPC03090-P	Antagonist	7.29	pKi
TY-52156	Antagonist	6.96	pKi
VPC44116	Antagonist	6.52	pKi
VPC12249	Agonist	6.5	pEC50
ASP4058	Agonist	6.04	pEC50
mocravimod-phosphate	Partial agonist	6.0	pEC50
AUY954	Agonist	5.96	pEC50
VPC23019	Antagonist	5.93	pKi
ponesimod	Agonist	5.68	pIC50
siponimod	Agonist	5.3	pEC50
compound 43 [PMID: 26751273]	Agonist	5.1	pEC50
proximod	Agonist	5.0	pEC50
ozanimod	Agonist	5.0	pEC50
compound 26 [PMID: 16190743]	Agonist	4.9	pIC50

Binding affinities (BindingDB)

2197 measured of 2911 human assays (2930 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-[N’-(1,3-benzothiazol-2-yl)-N-propanoylcarbamimidoyl]propanamide	EC50	0.0019 nM
1-[6-(4-ethoxy-3-methoxy-phenyl)-3-(methylthio)-6H-[1,2,4]triazino[5,6-d][3,1]benzoxazepin-7-yl]ethanone	EC50	0.00238 nM
[(2S)-2-amino-3-hydroxy-2-[2-(4-octylphenyl)ethyl]propoxy]phosphonic acid	EC50	0.006 nM
CHEMBL3806205	EC50	0.006 nM
CHEMBL2018323	EC50	0.00631 nM
[(1R,3S)-1-amino-3-[(6S)-6-[2-(2-methoxyphenyl)ethyl]-5,6,7,8-tetrahydronaphthalen-2-yl]cyclopentyl]methyl dihydrogen phosphate	EC50	0.008 nM	US-9522888: Substituted bicyclic compounds
CHEMBL2018176	EC50	0.0126 nM
(R)-2-amino-2-((S)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl)propyl dihydrogen phosphate	EC50	0.018 nM
CHEMBL2032301	EC50	0.0251 nM
(2S,3R,4E)-2-amino-3-hydroxyoctadec-4-en-1-yl dihydrogen phosphate	EC50	0.027 nM
CHEMBL4093489	EC50	0.027 nM
3-(4-(5-(3-cyano-4-(1,1,1-trifluoropropan-2-yloxy)phenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.03 nM
CHEMBL2018320	EC50	0.0316 nM
CHEMBL2032428	EC50	0.0316 nM
CHEMBL2032430	EC50	0.0316 nM
CHEMBL2011746	EC50	0.0398 nM
CHEMBL2018321	EC50	0.0398 nM
CHEMBL3358955	EC50	0.041 nM
CHEMBL2018319	EC50	0.0501 nM
3-(4-(5-(4-(S)-sec-butoxy-3-cyanophenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.07 nM
2-amino-3-hydroxy-2-((R)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl)propyl dihydrogen phosphate	EC50	0.077 nM
CHEMBL2018322	EC50	0.0794 nM
CHEMBL2032434	EC50	0.0794 nM
3-(3-methyl-4-{5-[4-(propan-2-yloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}phenyl)propanoic acid	EC50	0.08 nM
3-(4-{5-[3-cyano-4-(propan-2-yloxy)phenyl]-1,2,4-oxadiazol-3-yl}-3-methylphenyl)propanoic acid	EC50	0.08 nM
(R)-2-amino-2-((R)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl)propyl dihydrogen phosphate	EC50	0.088 nM
N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[2-methyl-6-(2-methylpropyl)-4-pyridinyl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	EC50	0.1 nM	US-9617250: Pyridin-4-yl derivatives
N-[(2S)-3-[4-[5-(2-cyclopentyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	EC50	0.1 nM	US-9617250: Pyridin-4-yl derivatives
N-[(2S)-3-[2-ethyl-6-methyl-4-[5-(2-pentan-3-yl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	EC50	0.1 nM	US-9617250: Pyridin-4-yl derivatives
[(1S,3R)-3-Amino-1-hydroxy-5-(4-octyl-phenyl)-pentyl]-phosphonic acid	IC50	0.1 nM
3-(4-(5-(3-cyano-4-(1,1,1,3,3,3-hexafluoropropan-2-yloxy)phenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.1 nM
3-(4-(5-(5-chloro-6-(1,1,1-trifluoropropan-2-yloxy)pyridin-3-yl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.1 nM
CHEMBL115713	IC50	0.1 nM
CHEMBL2032441	EC50	0.1 nM
CHEMBL3126588	EC50	0.1 nM
CHEMBL3126620	EC50	0.1 nM
CHEMBL3126622	EC50	0.1 nM
CHEMBL3126623	EC50	0.1 nM
CHEMBL3126584	EC50	0.1 nM
3-(4-(5-(3-cyano-4-(2,2,2-trifluoroethoxy)phenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.11 nM
3-(3-methyl-4-{5-[4-(propan-2-yloxy)-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl}phenyl)butanoic acid	EC50	0.12 nM
CHEMBL3359520	EC50	0.13 nM
[(2R)-2-amino-3-hydroxy-2-[2-(4-octylphenyl)ethyl]propoxy]phosphonic acid	EC50	0.14 nM
[4-[5-(3,4-diethoxyphenyl)-1,2,4-oxadiazol-3-yl]-2-pyridinyl]methanol	EC50	0.14 nM	US-10544136: Modulators of sphingosine phosphate receptors
5-(3,4-diethoxyphenyl)-3-(3-methyl-4-pyridinyl)-1,2,4-oxadiazole	EC50	0.15 nM	US-10544136: Modulators of sphingosine phosphate receptors
CHEMBL3359519	EC50	0.15 nM
3-(4-(5-(3-chloro-4-isopropoxyphenyl)-1,2,4-oxadiazol-3-yl)-3-methylphenyl)propanoic acid	EC50	0.15 nM
CHEMBL2032436	EC50	0.158 nM
[3-Amino-1-hydroxy-5-(4-octyl-phenyl)-pentyl]-phosphonic acid	IC50	0.16 nM
{2-[5-(4-Nonyl-phenyl)-pyrrolidin-2-yl]-ethyl}-phosphonic acid	IC50	0.16 nM

ChEMBL bioactivities

1979 potent at pChembl≥5 of 2074 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.40	IC50	0.04	nM	CHEMBL225155
10.00	EC50	0.1	nM	CHEMBL114606
9.87	EC50	0.134	nM	FTY720-P
9.82	EC50	0.15	nM	CHEMBL1089004
9.75	EC50	0.1778	nM	CHEMBL199791
9.70	EC50	0.2	nM	CHEMBL225155
9.67	EC50	0.215	nM	CHEMBL1091103
9.59	IC50	0.26	nM	CHEMBL225155
9.54	EC50	0.286	nM	CHEMBL1093686
9.44	IC50	0.36	nM	CHEMBL473156
9.40	IC50	0.4	nM	CHEMBL225155
9.35	EC50	0.449	nM	CHEMBL225155
9.18	IC50	0.66	nM	CHEMBL225155
9.15	IC50	0.71	nM	CHEMBL432067
9.15	EC50	0.7	nM	CHEMBL225155
9.05	IC50	0.9	nM	CHEMBL3655496
9.04	IC50	0.91	nM	CHEMBL119349
9.04	IC50	0.92	nM	CHEMBL225155
8.96	IC50	1.1	nM	CHEMBL333335
8.96	EC50	1.1	nM	CHEMBL225155
8.92	IC50	1.2	nM	CHEMBL119873
8.92	EC50	1.2	nM	CHEMBL3121986
8.92	EC50	1.2	nM	CHEMBL225155
8.92	IC50	1.2	nM	CHEMBL3655408
8.86	EC50	1.38	nM	CHEMBL473238
8.85	EC50	1.4	nM	CHEMBL114606
8.85	EC50	1.4	nM	CHEMBL3799355
8.80	EC50	1.6	nM	CHEMBL225155
8.77	EC50	1.7	nM	CHEMBL190006
8.70	EC50	2	nM	CHEMBL114606
8.70	EC50	2	nM	FTY720-P
8.70	IC50	2	nM	CHEMBL117031
8.62	EC50	2.4	nM	CHEMBL225155
8.62	EC50	2.4	nM	CHEMBL3126589
8.60	EC50	2.5	nM	CHEMBL190006
8.57	IC50	2.7	nM	CHEMBL117973
8.57	IC50	2.7	nM	CHEMBL118860
8.57	IC50	2.7	nM	CHEMBL184879
8.57	IC50	2.7	nM	CHEMBL119256
8.55	IC50	2.8	nM	CHEMBL184879
8.55	IC50	2.8	nM	CHEMBL118265
8.52	EC50	3	nM	FTY720-P
8.52	EC50	3	nM	FINGOLIMOD
8.52	IC50	3	nM	CHEMBL3741414
8.52	IC50	3	nM	CHEMBL3655407
8.52	IC50	3	nM	CHEMBL3655411
8.52	IC50	3	nM	CHEMBL3659686
8.52	EC50	3	nM	CHEMBL225155
8.51	IC50	3.1	nM	CHEMBL118860
8.51	EC50	3.1	nM	FTY720-P

PubChem BioAssay actives

938 with measured affinity, of 2196 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[(E,2S,3R)-2-amino-3-hydroxyoctadec-4-enyl] dihydrogen phosphate	204054: Inhibition of [33P]-S1P binding to human Sphingosine 1-phosphate receptor 3 expressed on CHO cell membranes	ic50	<0.0001	uM
[(2S)-2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate	473718: Agonist activity at human S1P3 receptor assessed as effect on calcium mobilization by Gi dependent whole cell assay	ec50	0.0001	uM
[(2R)-2-amino-2-[(2R)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl]propyl] dihydrogen phosphate	473718: Agonist activity at human S1P3 receptor assessed as effect on calcium mobilization by Gi dependent whole cell assay	ec50	0.0001	uM
[2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate	284811: Activity at human S1P3 receptor expressed in HEK293T cells by [35S]GTP-gamma-S binding assay	ec50	0.0001	uM
[2-amino-3-hydroxy-2-[(2R)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl]propyl] dihydrogen phosphate	473718: Agonist activity at human S1P3 receptor assessed as effect on calcium mobilization by Gi dependent whole cell assay	ec50	0.0002	uM
[(E,2S,3R)-2-amino-3-hydroxypentadec-4-enyl] dihydrogen phosphate	258418: Binding potency at human S1P3 receptor by [35S]GTP-gamma-S binding assay	ec50	0.0002	uM
[(2R)-2-amino-2-[(2S)-6-octyl-1,2,3,4-tetrahydronaphthalen-2-yl]propyl] dihydrogen phosphate	473718: Agonist activity at human S1P3 receptor assessed as effect on calcium mobilization by Gi dependent whole cell assay	ec50	0.0003	uM
[(2S)-2-amino-2-methyl-3-oxo-3-[4-(5-phenylpentoxy)anilino]propyl] dihydrogen phosphate	351685: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0004	uM
[2-amino-4-(4-octylphenyl)butyl] dihydrogen phosphate	1474270: Displacement of [33P]-S1P from human S1P3 receptor expressed in CHO cell membranes	ic50	0.0007	uM
3-(10-phenyldecylamino)propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0009	uM
3-[(4-nonoxyphenyl)methylamino]propylphosphonic acid	204052: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0011	uM
3-[(3-fluoro-4-octoxyphenyl)methylamino]propylphosphonic acid	204052: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0012	uM
N-[(2S)-3-[2-ethyl-6-methyl-4-[5-(3,5,5-triethyl-6,7-dihydro-4H-2-benzothiophen-1-yl)-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1071199: Agonist activity at human recombinant S1P3 receptor expressed in CHO cells assessed as membrane-bound 35S-GTPgammaS incubated 30 mins prior to substrate addition measured after 1 hr by topcount scintillation counting analysis	ec50	0.0012	uM
N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[3-[[methyl(2-methylpropyl)amino]methyl]-5-propan-2-ylphenyl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1297733: Agonist activity at human recombinant S1PR3 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding preincubated for 30 mins followed by [35S]GTPgammaS addition measured after 1 hr by topcount analysis	ec50	0.0014	uM
[(2S)-2-amino-2-methyl-3-oxo-3-[4-[3-(4-phenylphenyl)propoxy]anilino]propyl] dihydrogen phosphate	351689: Agonist activity at human S1P3 receptor assessed as stimulation of [35S]GTPgammaS binding	ec50	0.0014	uM
[(2R)-2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butyl] dihydrogen phosphate	305221: Activity at human recombinant S1P3 receptor expressed in CHO cells assessed as increase in calcium release by FLIPR assay	ec50	0.0017	uM
(3-amino-13-phenyltridecyl)phosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0020	uM
N-[(2S)-3-[4-[5-(2-cyclopentyl-6-ethyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1073713: Agonist activity at human recombinant S1P3 receptor expressed in CHO cells incubated for 30 mins prior to [35S]-GTPgammaS addition measured after 1 hr by topcount scintillation counting analysis	ec50	0.0024	uM
3-[(4-octylphenyl)methylamino]propylphosphonic acid	1474270: Displacement of [33P]-S1P from human S1P3 receptor expressed in CHO cell membranes	ic50	0.0027	uM
3-[(4-nonylphenyl)methylamino]propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0027	uM
3-(pentadecylamino)propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0027	uM
2-[5-(4-nonylphenyl)pyrrolidin-2-yl]ethylphosphonic acid	241961: Inhibition of [33P]-S1P binding to human Sphingosine 1-phosphate receptor 3 expressed on CHO cell membranes	ic50	0.0027	uM
3-(tridecylamino)propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0028	uM
Fingolimod	1054254: Agonist activity at S1P3 receptor (unknown origin)	ec50	0.0030	uM
[(1R,3R)-1-amino-3-(4-octoxyphenyl)cyclopentyl]methyl dihydrogen phosphate	1264658: Displacement of [33P]S1P from S1P3 receptor (unknown origin) expressed in HEK cell membranes after 45 to 60 mins by scintillation counting based RLB method	ic50	0.0030	uM
N-[(2S)-3-[2-ethyl-6-methyl-4-[5-[3-[[methyl(2-methylpropyl)amino]methyl]-5-propylphenyl]-1,2,4-oxadiazol-3-yl]phenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1297733: Agonist activity at human recombinant S1PR3 expressed in CHO cell membranes assessed as [35S]GTPgammaS binding preincubated for 30 mins followed by [35S]GTPgammaS addition measured after 1 hr by topcount analysis	ec50	0.0035	uM
3-(tetradecylamino)propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0036	uM
[(2S)-2-amino-3-(2-fluoro-4-octoxyanilino)-2-methyl-3-oxopropyl] dihydrogen phosphate	392390: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0036	uM
N-[(2S)-3-[2-ethyl-4-[5-(2-ethyl-6-pentan-3-yl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1073713: Agonist activity at human recombinant S1P3 receptor expressed in CHO cells incubated for 30 mins prior to [35S]-GTPgammaS addition measured after 1 hr by topcount scintillation counting analysis	ec50	0.0036	uM
1-[[4-[5-[4-(2-methylbutan-2-yl)phenyl]-1,2,4-oxadiazol-3-yl]phenyl]methyl]azetidine-3-carboxylic acid	255014: Concentration required for displacement of [33P]-labeled S1P from human sphingosine 1-phosphate receptor 3 expressed in CHO cells	ic50	0.0039	uM
[2-amino-4-[4-(2-fluoro-4-phenylmethoxyphenyl)phenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate	475241: Agonist activity at human S1P3 receptor expressed in CHO cells assessed as intracellular calcium mobilization	ec50	0.0041	uM
3-[2-(4-octylphenyl)ethylamino]propylphosphonic acid	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0043	uM
[(1S,3S)-3-[(4-nonylphenyl)methylamino]cyclohexyl]phosphonic acid	241961: Inhibition of [33P]-S1P binding to human Sphingosine 1-phosphate receptor 3 expressed on CHO cell membranes	ic50	0.0047	uM
3-[(3-chloro-4-octoxyphenyl)methylamino]propylphosphonic acid	204052: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0049	uM
[2-amino-4-[4-(2-fluoro-4-phenylsulfanylphenyl)phenyl]-2-(hydroxymethyl)butyl] dihydrogen phosphate	475241: Agonist activity at human S1P3 receptor expressed in CHO cells assessed as intracellular calcium mobilization	ec50	0.0049	uM
[(E,2S,3R)-2-amino-3-hydroxy-15-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]pentadec-4-enyl] dihydrogen phosphate	258418: Binding potency at human S1P3 receptor by [35S]GTP-gamma-S binding assay	ec50	0.0050	uM
N-[(2S)-3-[4-[5-(2-cyclobutyl-6-ethyl-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-2-hydroxypropyl]-2-hydroxyacetamide	1073713: Agonist activity at human recombinant S1P3 receptor expressed in CHO cells incubated for 30 mins prior to [35S]-GTPgammaS addition measured after 1 hr by topcount scintillation counting analysis	ec50	0.0050	uM
2-[(2R,5S)-5-tetradecylpyrrolidin-2-yl]ethylphosphonic acid	241961: Inhibition of [33P]-S1P binding to human Sphingosine 1-phosphate receptor 3 expressed on CHO cell membranes	ic50	0.0052	uM
[(2R)-2-amino-2-[5-(4-octoxyphenyl)-1H-imidazol-2-yl]propyl] dihydrogen phosphate	392390: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0053	uM
[(2S)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate	466804: Agonist activity at human S1P3 receptor expressed in CHO cells assessed as induction of [S35]GTPgammaS binding	ec50	0.0054	uM
[(Z)-2-amino-3-hydroxyoctadec-4-enyl] dihydrogen phosphate	1798300: [32P] S1P Binding Assay from Article 10.1016/j.bmc.2004.10.008: “Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate.”	ki	0.0054	uM
[(2R)-2-amino-2-[5-(3-fluoro-4-octoxyphenyl)-1H-imidazol-2-yl]propyl] dihydrogen phosphate	392390: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0058	uM
3-[2-[2-ethyl-4-[5-(3-ethyl-5,5-dimethyl-6,7-dihydro-4H-2-benzothiophen-1-yl)-1,2,4-oxadiazol-3-yl]-6-methylphenoxy]ethylamino]propanoic acid	1071199: Agonist activity at human recombinant S1P3 receptor expressed in CHO cells assessed as membrane-bound 35S-GTPgammaS incubated 30 mins prior to substrate addition measured after 1 hr by topcount scintillation counting analysis	ec50	0.0058	uM
[(2S)-2-amino-2-methyl-3-(4-octoxyanilino)-3-oxopropyl] dihydrogen phosphate	392390: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0059	uM
[(2S)-2-amino-3-(3-fluoro-4-octoxyanilino)-2-methyl-3-oxopropyl] dihydrogen phosphate	392390: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0059	uM
3-[(3-methyl-4-octoxyphenyl)methylamino]propylphosphonic acid	204052: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0060	uM
[(2R)-2-amino-2-[5-[4-(5-phenylpentoxy)phenyl]-1H-imidazol-2-yl]propyl] dihydrogen phosphate	351685: Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	ic50	0.0060	uM
[(2R)-2-amino-4-(4-heptoxyphenyl)-2-methylbutyl] dihydrogen phosphate	258418: Binding potency at human S1P3 receptor by [35S]GTP-gamma-S binding assay	ec50	0.0063	uM
[2-amino-1-hydroxy-4-(4-octylphenyl)butan-2-yl] dihydrogen phosphate	204051: Binding affinity to human sphingosine 1-phosphate receptor 3 expressed in CHO cells was determined by using [33P]-S1P as radioligand	ic50	0.0063	uM
[2-amino-2-(hydroxymethyl)-4-(4-octylphenyl)butoxy]-trihydroxyphosphanium	241961: Inhibition of [33P]-S1P binding to human Sphingosine 1-phosphate receptor 3 expressed on CHO cell membranes	ic50	0.0063	uM

CTD chemical–gene interactions

71 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
trichostatin A	decreases expression, increases expression, increases reaction, affects cotreatment, affects expression	5
Benzo(a)pyrene	increases expression, increases methylation, affects methylation	4
sphingosine 1-phosphate	decreases reaction, increases expression, affects reaction	3
Estradiol	affects binding, increases expression, decreases expression	3
Valproic Acid	decreases expression, increases expression, increases methylation	3
bisphenol A	affects cotreatment, decreases methylation, increases expression	2
entinostat	affects cotreatment, decreases expression	2
belinostat	decreases expression, affects cotreatment	2
Resveratrol	affects cotreatment, decreases expression, increases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Air Pollutants	decreases expression, increases abundance, increases expression	2
Nickel	increases expression	2
Smoke	decreases expression, increases expression	2
Tretinoin	decreases expression, increases expression	2
1-Methyl-4-phenylpyridinium	decreases expression, increases expression	2
Cyclosporine	decreases expression	2
Cadmium Chloride	decreases expression	2
Simvastatin	increases expression, decreases expression	2
Genistein	decreases expression, increases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
VPC23019	decreases activity	1
daidzein	affects cotreatment, decreases expression	1
methylmercuric chloride	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
daidzin	affects cotreatment, decreases expression	1
o,p’-DDT	increases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	decreases expression	1
butylbenzyl phthalate	affects reaction, increases expression, increases reaction	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1

ChEMBL screening assays

225 unique, capped per target: 123 functional, 94 binding, 8 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3386601	Functional	Agonist activity at S1P2/3 receptor in HEK293 cells assessed as inhibition of forskolin-induced cAMP level after 1 hr by alphascreen immunoassay	The design and implementation of a generic lipopeptide scanning platform to enable the identification of ’locally acting’ agonists for the apelin receptor. — *Bioorg Med Chem Lett*
CHEMBL1029036	Binding	Displacement of [33P]sphingosine-1-phosphate from human S1P3 receptor	Synthesis and evaluation of alkoxy-phenylamides and alkoxy-phenylimidazoles as potent sphingosine-1-phosphate receptor subtype-1 agonists. — *Bioorg Med Chem Lett*
CHEMBL3876453	ADMET	Agonist activity at recombinant human S1PR3 expressed in CHO cell membranes assessed as [35S]GTP-gammaS binding measured after 1.5 hrs by TopCount scintillation counting method	A benzo[b]thiophene-based selective type 4 S1P receptor agonist. — *Bioorg Med Chem Lett*

Cellosaurus cell lines

11 cell lines: 6 cancer cell line, 3 transformed cell line, 2 spontaneously immortalized cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D7ZW	Ubigene A-549 S1PR3 KO	Cancer cell line	Male
CVCL_D9R8	Ubigene HEK293 S1PR3 KO	Transformed cell line	Female
CVCL_E0N6	Ubigene HeLa S1PR3 KO	Cancer cell line	Female
CVCL_E1K3	HyCyte HCT 116 KO-hS1PR3	Cancer cell line	Male
CVCL_KA18	RH7777/EDG3	Cancer cell line	Female
CVCL_KU53	CHO-K1 EDG3 Gq	Spontaneously immortalized cell line	Female
CVCL_KW94	PathHunter CHO-K1 EDG3 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_KZ46	PathHunter HEK 293 EDG3 beta-arrestin	Transformed cell line	Female
CVCL_LA23	PathHunter U2OS EDG3 Activated GPCR Internalization	Cancer cell line	Female
CVCL_ZI79	GeneBLAzer EDG3-Galpha15-NFAT-bla HEK 293T	Transformed cell line	Female

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for S1PR3 across ~30M SureChEMBL compounds — explore on Sugi Predict.